Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling

Cancer Letters

Volumn 273, Issue 2, 2009, Pages 292-299

  Zhou, Hui ^a   Huang, Liqun ^a   Sun, Yu ^a   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Cell signaling; Chemoprevention; NO aspirin; NO NSAIDs; Pancreatic cancer; ROS

Indexed keywords

2 (ACETYLOXY)BENZOIC ACID 4 (NITROOXYMETHYL)PHENYL ESTER; ACETYLCYSTEINE; ACETYLSALICYLIC ACID DERIVATIVE; ACTIVATING TRANSCRIPTION FACTOR 2; BETA ACTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C JUN; PROTEIN P21; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; COX 2 GENE; DRUG MECHANISM; ENZYME ACTIVATION; GENE; HUMAN; HUMAN CELL; IC 50; OXIDATION REDUCTION POTENTIAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ASPIRIN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; HUMANS; INHIBITORY CONCENTRATION 50; NECROSIS; NITRIC OXIDE; OXIDATION-REDUCTION; PANCREATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 57349145254     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.08.006     Document Type: Article

References (28)

1. Samra J.S., Gananadha S., and Hugh T.J. Surgical management of carcinoma of the head of pancreas: extended lymphadenectomy or modified en bloc resection?. ANZ J. Surg. 78 (2008) 228-236
2. Hart A.R., Kennedy H., and Harvey I. Pancreatic cancer: a review of the evidence on causation. Clin. Gastroenterol. Hepatol. 6 (2008) 275-282
3. Boeck S., and Heinemann V. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol. 4 (2008) 41-50
4. Ouyang N., Williams J.L., Tsioulias G.J., Gao J., Iatropoulos M.J., Kopelovich L., Kashfi K., and Rigas B. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 66 (2006) 4503-4511
5. Rigas B. The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr. Opin. Gastroenterol. 23 (2007) 55-59
6. Gao J., Liu X., and Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl. Acad. Sci. USA 102 (2005) 17207-17212
7. Rigas B., and Sun Y. Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br. J. Cancer 98 (2008) 1157-1160
8. Hundley T.R., and Rigas B. Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J. Pharmacol. Exp. Ther. 316 (2006) 25-34
9. Williams J.L., Ji P., Ouyang N., Liu X., and Rigas B. NO-donating aspirin inhibits the activation of NF-{kappa}B in human cancer cell lines and Min mice. Carcinogenesis 29 (2008) 199-204
10. Williams J.L., Nath N., Chen J., Hundley T.R., Gao J., Kopelovich L., Kashfi K., and Rigas B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res. 63 (2003) 7613-7618
11. Spiegel A., Hundley T.R., Chen J., Gao J., Ouyang N., Liu X., Go M.F., Tsioulias G.J., Kashfi K., and Rigas B. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem. Pharmacol. 70 (2005) 993-1000
12. Nath N., Kashfi K., Chen J., and Rigas B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc. Natl. Acad. Sci. USA 100 (2003) 12584-12589
13. Ding X.Z., Tong W.G., and Adrian T.E. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology 1 (2001) 291-299
14. Sarkar F.H., Adsule S., Li Y., and Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev. Med. Chem. 7 (2007) 599-608
15. Baron J.A. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog. Exp. Tumor Res. 37 (2003) 1-24
16. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., Anderson G.D., Burton E.G., Cogburn J.N., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Veenhuizen A.W., Zhang Y.Y., and Isakson P.C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J. Med. Chem. 40 (1997) 1347-1365
17. Yeh R.K., Chen J., Williams J.L., Baluch M., Hundley T.R., Rosenbaum R.E., Kalala S., Traganos F., del Soldato P., Kashfi K., and Rigas B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?. Biochem. Pharmacol. 67 (2004) 2197-2205
18. Bass D.A., Parce J.W., Dechatelet L.R., Szejda P., Seeds M.C., and Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J. Immunol. 130 (1983) 1910-1917
19. LeBel C.P., Ischiropoulos H., and Bondy S.C. Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 5 (1992) 227-231
20. Santamaria D., and Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front. Biosci. 11 (2006) 1164-1188
21. Pei X.H., and Xiong Y. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 24 (2005) 2787-2795
22. Weiss R.H. P21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4 (2003) 425-429
23. Junttila M.R., Li S.P., and Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J. 22 (2008) 954-965
24. Pimienta G., and Pascual J. Canonical and alternative MAPK signaling. Cell Cycle 6 (2007) 2628-2632
25. Zahner G., Wolf G., Ayoub M., Reinking R., Panzer U., Shankland S.J., and Stahl R.A. Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1. J. Biol. Chem. 277 (2002) 9763-9771
26. Frein D., Schildknecht S., Bachschmid M., and Ullrich V. Redox regulation: a new challenge for pharmacology. Biochem. Pharmacol. 70 (2005) 811-823
27. Rigas B., and Kashfi K. Cancer prevention: a new era beyond cyclooxygenase-2. J. Pharmacol. Exp. Ther. 314 (2005) 1-8
28. Hayashi T., Ueno Y., and Okamoto T. Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J. Biol. Chem. 268 (1993) 11380-11388